Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis

References

• Talbot K. Motor neuron disease: the bare essentials. Pract Neurol. 2009;9:303–9.
   Google Scholar
• Veldink JH, Wokke JHJ, van der Wal G, Vianney de Jong JMB, van den Berg LH. Euthanasia and Physician-Assisted Suicide among Patients with Amyotrophic Lateral Sclerosis in the Netherlands. N Engl J Med. 2002;346:1638–44.
   PubMed Web of Science ®Google Scholar
• Johnston CA, Stanton BR, Turner MR, Gray R, Blunt AH, Butt D, et al. Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol. 2006;253:1642–3.
   PubMed Web of Science ®Google Scholar
• Zinman L, Cudkowicz M. Emerging targets and treatments in amyotrophic lateral sclerosis. The Lancet Neurol. 2011; 10:481–90.
   PubMed Web of Science ®Google Scholar
• NICE. Guide to the methods of technology appraisal.2008; June.
   Google Scholar
• EuroQol. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16: 199–208.
   PubMed Web of Science ®Google Scholar
• Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012;135:847–52.
   PubMed Web of Science ®Google Scholar
• Winter Y, Schepelmann K, Spottke A, Claus D, Grothe C, Schröder R, et al. Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol. 2010;257:1473–81.
   PubMed Web of Science ®Google Scholar
• UKMND-LiCALS GS. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12:339–45.
   PubMed Web of Science ®Google Scholar
• Al-Chalabi A, Shaw P, Young C, Morrison K, Murphy C, Thornhill M, et al. Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic Lateral Sclerosis (LiCALS) [Eudract number: 2008-006891-31]. BMC Neurol. 2011;11:111.
   PubMed Web of Science ®Google Scholar
• Dolan P, Stalmeier P. The validity of time trade-off values in calculating QALYs: constant proportional time trade-off versus the proportional heuristic. J Health Econ. 2003;22: 445–58.
   PubMed Web of Science ®Google Scholar
• Greiner W, Claes C, Busschbach JJV, Schulenburg JM. Validating the EQ-5D with time trade off for the German population. Eur J Health Econ. 2005;6:124–30.
   PubMedGoogle Scholar
• Dolan P. Modelling valuations for health states: the effect of duration. Health policy. 1996;38:189–203.
   PubMed Web of Science ®Google Scholar
• Gibbons C, Mills R, Thornton E, Ealing J, Mitchell J, Shaw P, et al. Rasch analysis of the Hospital Anxiety and Depression Scale (HADS) for use in motor neurone disease Health Qual Life Outcomes. 2011;9:82.
   Google Scholar
• Kiebert GM, Green C, Murphy C, Mitchell JD, O’Brien M, Burrell A, et al. Patients’ health-related quality of life and utilities associated with different stages of amyotrophic lateral sclerosis. J Neurol Sci. 2001;191:87–93.
   PubMed Web of Science ®Google Scholar
• Norquist JM, Jenkinson C, Fitzpatrick R, Swash M. Factors which predict physical and mental health status in patients with amyotrophic lateral sclerosis over time. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:112–7.
   PubMed Web of Science ®Google Scholar
• Chiò A, Gauthier A, Montuschi A, Calvo A, Di Vito N, Ghiglione P, et al. A cross sectional study on determinants of quality of life in ALS. J Neurol Neurosurg Psychiatry. 2004;75:1597–601.
   PubMed Web of Science ®Google Scholar
• Jenkinson C, Fitzpatrick R, Swash M, Peto V. The ALS Health Profile Study: quality of life of amyotrophic lateral sclerosis patients and carers in Europe. J Neurol. 2000; 247:835–40.
   PubMed Web of Science ®Google Scholar
• De Groot IJM, Post MWM, Heuveln Tv, Van den Berg LH, Lindeman E. Cross-sectional and longitudinal correlations between disease progression and different health-related quality of life domains in persons with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2007;8:356–61.
   PubMed Web of Science ®Google Scholar
• Averill A, Kasarskis E, Segerstrom S. Psychological health in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2007;8:243–54.
   PubMed Web of Science ®Google Scholar
• Dolan P. Using Happiness to Value Health. London, UK: Office of Health Economics. 2011 (Report No. 1).
   Google Scholar
• Jensen MP, Abresch RT, Carter GT, McDonald CM. Chronic Pain in Persons With Neuromuscular Disease. Arch Phys Med Rehabil. 2005;86:1155–63.
   PubMed Web of Science ®Google Scholar
• Behari M, Srivastava AK, Pandey RM. Quality of life in patients with Parkinson’s disease. Parkinsonism Relat Disord. 2005;11:221–6.
   PubMed Web of Science ®Google Scholar
• Ho AK, Gilbert AS, Mason SL, Goodman AO, Barker RA. Health-related quality of life in Huntington’s disease: Which factors matter most?Mov Disord. 2009;24:574–8.
   PubMed Web of Science ®Google Scholar
• Oh H, Sin M-K, Schepp KG, Choi-Kwon S. Depressive Symptoms and Functional Impairment Among Amyotrophic Lateral Sclerosis Patients in South Korea. Rehabil Nurs. 2012;37:136–44.
   PubMed Web of Science ®Google Scholar
• Rabkin JG, Wagner GJ, Del Bene M. Resilience and Distress Among Amyotrophic Lateral Sclerosis Patients and Caregivers. Psychosom Med. 2000;62:271–9.
   PubMed Web of Science ®Google Scholar
• Lillo P, Mioshi E, Zoing MC, Kiernan MC, Hodges JR. How common are behavioural changes in amyotrophic lateral sclerosis?Amyotroph Lateral Scler. 2011;12:45–51.
   PubMed Web of Science ®Google Scholar
• Mendez MF, Perryman KM. Neuropsychiatric Features of Frontotemporal DementiaEvaluation of Consensus Criteria and Review. J Neuropsychiatry Clin Neurosci. 2002;14: 424–9.
   PubMed Web of Science ®Google Scholar